Results 31 to 40 of about 1,049,512 (355)
BMC Gastroenterology, 2018 Background Calprotectin is a stable neutrophil protein, which can be measured in faecal samples. The faecal level of calprotectin increases during disease activity in ulcerative colitis (UC).
Takahiro Shimoyama +3 more
doaj +1 more source
Have advances in medical therapy for ulcerative colitis impacted surgical treatment?
Annals of Gastroenterological Surgery, 2023 Aim The purpose of this study was to examine how the clinical characteristics, indications for surgery, and postoperative course of ulcerative colitis (UC) surgical patients changed before and after the introduction of biological agents. Methods Patients
Ryuichi Kuwahara +5 more
doaj +1 more source
The burden of inflammatory bowel disease in Europe in 2020.
Journal of Crohn's & Colitis, 2021 New data suggest that incidence and prevalence of inflammatory bowel diseases (IBD) are still increasing worldwide, and approximately 0.2% of the European population suffers from IBD at the present time.
Mirabella Zhao +3 more
semanticscholar +1 more source
Metalloproteinases in Inflammatory Bowel Diseases
Journal of Inflammation Research, 2021 Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the gastrointestinal tract, encompassing two main disorders: Crohn's disease (CD) and ulcerative colitis (UC). In both these pathologies, excessive and local immune response against luminal antigens promotes a pathological process leading to various degrees of gut damage.
Maronek M. +5 more
openaire +7 more sources
Scientific Reports, 2021 Intestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects.
Laura Sanchis-Artero +11 more
doaj +1 more source
Review of the safety with biologics in inflammatory bowel disease
Journal of IMIDs, 2022 Biologics have completely changed the treatment (and life) of patients with inflammatory bowel disease (IBD). After the first ones, anti-tumor necrosis factor (TNF) biologics, two new biologics, with other therapeutic targets, are now in routine use in ...
Andrea Pascual +3 more
doaj +1 more source
Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study [PDF]
Intestinal Research, 2022 Background/Aims Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists.
Masaaki Usami +8 more
doaj +1 more source
Gut microbiome structure and metabolic activity in inflammatory bowel disease
Nature Microbiology, 2018 The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract.
E. Franzosa +26 more
semanticscholar +1 more source
Gastroenterology, 2004 Although the incidence and prevalence of ulcerative colitis and Crohn's disease are beginning to stabilize in high-incidence areas such as northern Europe and North America, they continue to rise in low-incidence areas such as southern Europe, Asia, and ...
E. Loftus
semanticscholar +1 more source
Inflammatory bowel disease biomarkers
Medicinal research reviews (Print), 2022 Inflammatory bowel disease (IBD) is characterized as chronic inflammation in the gastrointestinal tract, which includes two main subtypes, Crohn's disease and ulcerative colitis.
Dandan Liu +4 more
semanticscholar +1 more source